Latest filingSep 02, 2026Most recent Form 4
HALO
HALOZYME THERAPEUTICS, INC.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$627M11 sells
Net open-market-$627M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period19transactions
- S · Open-market sells · dominant11 · 58%
- M · Option exercise6 · 32%
- A · Grants / awards2 · 11%
Activity by reported role
A joint filing can contribute to multiple roles19transactions
- PRES · dominant17 · 89%
- Director2 · 11%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (1)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeTorley HelenCommon Stock · Direct
787,780Aug 19, 2026
Torley HelenOption to Purchase Common Stock · Direct
141,552Aug 19, 2026
Appelhans DannielleOption to Purchase Common Stock · Direct
1,778Sep 01, 2026
Appelhans DannielleRestricted Stock Units · Direct
1,161Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- TH-$6.3M
Recent filing activity
Most recent 11 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
HALO transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| HALO | Torley Helen | PRES | sale10b5-1 | 3.20k | -$34.4M | S | +1.5% | 08/20 | 08/19 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 9.60k | -$102M | S | +1.5% | 08/20 | 08/19 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 7.20k | -$76.5M | S | +1.5% | 08/20 | 08/19 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 9.40k | -$98.5M | S | +1.5% | 08/20 | 08/18 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 4.89k | -$50.9M | S | +1.5% | 08/20 | 08/18 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 5.70k | -$58.7M | S | +1.5% | 08/20 | 08/18 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 7.50k | -$77.6M | S | +1.5% | 08/20 | 08/17 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 9.00k | -$92.2M | S | +1.5% | 08/20 | 08/17 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 2.10k | -$21.3M | S | +1.5% | 08/20 | 08/17 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 500 | -$5.02M | S | +1.5% | 08/20 | 08/17 | |
| HALO | Torley Helen | PRES | sale10b5-1 | 900 | -$8.90M | S | +1.5% | 08/20 | 08/17 |
HALOZYME THERAPEUTICS, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at HALOZYME THERAPEUTICS, INC.?
Appelhans Dannielle, Torley Helen.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Torley Helen reported a sale on Aug 19, 2026 valued at $34.4M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $6,275,591.92. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.